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Summary
Purpose and background: We examined whether patients with
colon cancer undergoing surgery with or without adjuvant
chemotherapy change the internal standards on which they
base their quality-of-life (QL) estimation, and, if they do so,
whether this reframing alters interpretation of QL findings.
These questions were addressed within a randomized clinical
trial of the Swiss Group for Clinical Cancer Research (SAKK
40/93).
Patients and methods: After radical resection of adenocar-
cinoma of the colon (pT|_4pN>0M0 and pT3_4pNoMo) and
perioperative chemotherapy, patients were randomized to
three treatment arms: observation only (A), 5-FU 450 rag/m2
plus Levamisol (B), or 5-FU 600 mg/m2 (C). QL was measured
by linear analogue self-assessment indicators. Patients estimated
their pre-surgery QL both before surgery and retrospectively
thereafter, and their pre-adjuvant QL both at the beginning of
randomly assigned chemotherapy or observation and retro-
spectively about two months later. Thereafter, current QL was
assessed. Paired Mests were used to test the hypotheses of no
change.
Results: Overall, 187 patients with at least one pair of
corresponding questionnaires were analyzed. Patients estimated
their pre-surgery QL after surgery significantly lower than
before and their pre-adjuvant QL under treatment or observa-
tion also lower than at the beginning. In the adjuvant phase, in
contradiction to our hypothesis, chemotherapy had almost no
impact on these changes attributed to reframing. Convention-
ally assessed changes indicated an improvement in QL. Patients
with treatment C reported less improvement in functional
performance than those with B or those under observation
(P = 0.04). Patients with treatment B indicated a greater
worsening in nausea/vomiting than those with C, whereas
patients with observation only showed an improvement
(P — 0.0009). After adjustment of current QL scores under
treatment or observation to patients' retrospective estimation,
the treatment effects were diluted but the overall improvement
was substantially amplified in most QL indicators.
Conclusions: Patients with colon cancer substantially re-
frame their perception in estimating QL both under radical
resection and under adjuvant chemotherapy or observation.
This effect is an integral part of patients' adaptation to disease
and treatment. An understanding of this phenomenon is of
particular relevance for patient care. Its role in evaluating QL
endpoints in clinical trials needs further investigation.
Key words: adjuvant therapy, colon cancer, quality of life,
randomized trial, reframing, response-shift
Introduction
"Stories we understand are only badly told."
B. Brecht, Baal
As clinicians or healthy individuals we tend to compare
a patient's current state of health with his or her state
preceding the diagnosis. However, there is some evidence
that patients with a chronic disease are 'reframing' their
internal standards of health in the process of becoming
and remaining ill. For example, a patient with bone
metastases stating "I feel good" may live in a seriously
impaired health status. 'Feeling good' may mean in this
case "I am happy as long as it doesn't get worse".
Adopting the point of view of a sick person is partic-
ularly important for understanding the subjective ex-
perience of disease and treatment. The process of re-
framing may include an internal recalibration of, e.g.,
the meaning of 'good' physical functioning, but also a
shift in personal values to a new understanding of what
constitutes one's quality of life (QL) [1], e.g., the increas-
ing importance of close relationships. This phenomenon
has also been described as 'response-shift' and is used to
interpret unexpected QL findings [2]. For example, pa-
tients with cancer and other chronic diseases, when
assessed with generic scales, such as for psychological
distress [3], show scores in the same range or even better
than healthy individuals. Although an understanding of
this phenomenon is of major importance for patient
care and QL research it has rarely been studied [4].
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We examined whether patients with newly diagnosed
colon cancer change the internal standards on which
they base their QL estimation, and, if they do so,
whether this reframing alters interpretation of QL find-
ings. These questions were addressed in regard to radical
resection with perioperative chemotherapy and randomly
assigned post-operative adjuvant chemotherapy or ob-
servation within a clinical trial of the Swiss Group for
Clinical Cancer Research (SAKK 40/93).*
Based on clinical observation, we expected that pa-
tients'estimates of their pre-surgery QL would be lower
after surgery compared to before. Patients tend to ex-
press an optimistic outlook after resection of the tumor
(e.g., 'the cancer has been cured')- However, they also
face surgical sequelae and are aware that it takes time to
recover [5]. Adjusting to the fundamental changes in
daily life provokes a shift in internal standards: Refram-
ing the past toward worse QL would fit this enlarged
experience and contribute to a favorable perception of
the present. The motivation for this shift may be an
understandable imperative to view one's condition in an
optimistic light and to consider one's life worth living.
This process may be termed mental homeostasis.
Similarly, we expected that the patients' retrospective
estimates of their QL at the beginning of adjuvant ther-
apy or observation would be lower than estimates made
beforehand. This reframing was expected to be stronger
in patients receiving chemotherapy compared to those
without: experiencing cytotoxic side-effects would in-
duce a greater shift in internal standards to regain
mental homeostasis. The latter hypothesis was tested
within the randomized trial design, and conventionally
assessed changes were compared with those taking into
account patients' reframing.
Patients and methods
The trial
The trial (SAKK 40/93) was open for all patients with radically
resected and histologically proven adenocarcinoma of the colon with
pathologically confirmed stages pT]_4pN>0M0 and pT3 4pN0M0. The
patients had to have a potentially curative resection (R0-resection) and
no additional rectal carcinoma. The perioperative intraportal chemo-
therapy was a seven-day infusion of 5-fluorouracil (5-FU) starting
immediately after surgery and interrupted by a two-hour infusion of
mitomycin-C after the first 24 hours. It had to be stopped in case of
serious toxicity. In case of technical problems with the recommended
intraportal catheter, switching to the intravenous route was possible.
The randomization for post-operative adjuvant chemotherapy had
to take place between 7 and 28 days after surgery, and was recom-
mended 2 to 3 days before hospital discharge. The patients were
assigned to three treatment arms: observation only (A); 5-FU 450
mg/m2 i.v. once weekly for one year plus every second week 50 mg
Levamisol orally every eight hours for three days (B); 5-FU 600 mg/m2
i.v. once weekly for one year (C). Stratification included institution,
age, tumor stage and administration of perioperative chemotherapy.
Criteria for dose modifications were specified in the protocol. Toxicity
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Figure 1. Quality of life assessment schedule regarding surgery.
was rated by physicians according to Early Clinical Trials Group
guidelines.
The QL investigation was restricted to centers in German speaking
areas of Switzerland, and to selected centers in Germany.
QL assessment
QL assessment included 15 linear analogue self assessment (LASA) [6]
indicators of components of QL, ranging from 0-100. Global measures
of well-being and functioning were complemented by specific measures
of tumor symptoms and treatment side-effects. Responses on the global
measures are expected to reflect the summation of the individual
meaning and importance of various factors for each patient [7], This
property makes these measures suitable for studying reframing effects:
The perception of a particular symptom and its relative importance
may vary over time and on/off treatment [7].
We expected reframing to affect primarily physical measures and
global measures associated with physical factors. The following seven
indicators were prospectively defined as primary endpoinls: physical
well-being, mood, tiredness, coping/perceived adjustment [8], appetite,
pain and overall QL. Functional performance, nausea/vomiting and
anxiety were selected as secondary endpoints to assess common side-
effects of 5-FU and of Levamisol, and to investigate consistency among
complementary domains. Most of these indicators have been validated
extensively [7, 9, 10] and used in various cancer sites [11-13].
As shown in Figure I, patients were asked to estimate their pre-
surgery QL both before surgery (surgery pre-test): "...We would like to
know how you felt during the last week before your surgery or any
other treatment...", and retrospectively after surgery (surgery 'then-
test' [14]): "...Please think back a moment to the time before your
surgery when you filled in the first questionnaire for us. Indicate on the
enclosed questionnaire how you felt during the last week before your
surgery...". The difference of the pre- and then-test was used as meas-
ure for reframing.
Both surgery pre- and then-test were assessed in the hospital after
oral instruction of the patient by a physician or nurse, in addition to
the written instruction indicated above. The surgery pre-test was to be
assessed by all patients eligible for the clinical trial, regardless if they
actually were randomized after surgery. The surgery then-test was to
be completed on the day of randomization (i.e., close to hospital
discharge). Sociodemographic data were also collected by the staff.
Similarly, following discharge, patients were asked to estimate their
QL at the beginning of randomly assigned adjuvant chemotherapy or
observation (adjuvant pre-test), as shown in Figure 2: "...Now that you
are back at home, we would like to follow-up on how you are doing...",
and retrospectively about two months later (adjuvant then-test): "'...We
are interested to find out what you now think about your well-being
two months ago...". Finally, patients' current QL under treatment or
observation (adjuvant post-test) was assessed about two weeks after
the adjuvant then-test: "...Please respond to all questions regarding
how you felt during the last week...". The adjuvant pre-test, then-test
0
 Part of these results were presented at the 21st Congress of the European Society for Medical Oncology, 1 5 November 1996. Vienna, Austria.
Abstract published in Ann Oncol 1996; 7 (Suppl): 38.
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Table 1. Biomedical and sociodemographic patient characteristics of
the total sample (n = 187).
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Figure 2. Quality of life assessment schedule regarding the adjuvant
phase.
and post-test were completed at home. Questionnaires were sent to
patients with a cover letter including the relevant instructions and a
stamped addressed envelope to send it back to the coordinating center.
For all assessments, the time to be evaluated was also specified in
the introductory statement to the questions on both pages of the
questionnaire. For global QL the wording of the indicator was ad-
justed: The surgery pre-test: "How do you rate your quality of life
during the last week", was phrased for the surgery then-test: "How do
you rate your quality of life before the operation"; the adjuvant pre-
test: "How do you rate your quality of life during the last week" was
phrased for the adjuvant then-test: "How do you rate your quality of
life during the time period approximately two months ago".
Statistical analysis
Submission rates of QL questionnaires were defined as the ratio of the
number of received and evaluable questionnaires to the number of
expected questionnaires in regard to various comparisons. The res-
ponders were compared with the non-responders regarding the bio-
medical and sociodemographic characteristics described in Table 1,
separately for the comparisons related to surgery and the adjuvant
phase.
The first hypothesis (i.e., worse scores of retrospective estimations)
was investigated by paired (-tests between the pre- and then-test
assessments separately for surgery and the adjuvant phase, the latter
separately by treatment and overall. The second hypothesis (i.e., worse
scores of retrospective estimations in patients with chemotherapy as
compared to those without) was investigated by F-tests of changes
between pre- and then-tests.
To control for factors with a potential impact on patients' percep-
tion of disease and treatment, the univariate analyses were comple-
mented by multiple linear regression analyses. This analysis was ex-
plorative. The best predictive model was chosen using Mallow's Cp as
criterion [15]. Biomedical factors included sex, age, family history of
colorectal carcinomas, type of surgery, and lymph nodes involved
(Table I). For the comparison related to surgery, surgical and medical
complications and duration of hospital stay were also included; for the
comparison in the adjuvant situation, treatment assignment and the
timing of QL assessment relative to the beginning of chemotherapy
were used. Sociodemographic factors included education, professional
position and living situation (Table 1). Finally, for both comparisons,
institution, a well-known prognostic factor in colon cancer surgery,
and the time interval between pre- and then-test were included.
Changes under adjuvant treatment or observation were conven-
tionally investigated by paired /-tests between the pre- and post-test
assessments separately by treatment and overall. In addition, patients'
reframing was taken into account by comparing the post-test to the
then-test instead of the conventional pre-test. To explore the discrim-
inative capacity of these two approaches, weekly assessments of physi-
cian rated nausea and vomiting (5-point scales) over the first three
months were used as an external criterion of a change induced by
chemotherapy.
We faced ranges in timing of QL assessment going beyond the
schedule defined in the protocol. However, we preferred to include all
Grouped categories
Sex
Male
Female
Age
<65
>65
Family history of colorectal cancer
Positive parents, grandparents, uncle, aunt, children/
other relatives
Negative
Not evaluable
Type of surgery
Right hemicolectomy/resection of transverse colon/
sigmoid resection
Left hemicolectomy
Otherb
Lymph node involvement
pN0
pN,/pN2/pN3
Living situation
With spouse or partner/with other(s)/alone with
child(ren)
Alone
Educational level
No training or certificate
Training or certificate/high school
Technical college/academic education
Last professional position
Laborer/employee
Subordinate manager/administrative position/
self-employed small trade/farmer
Upper level manager/academic professional/director
Housekeeper without external job
na (%)
110(59)
77(41)
107(57)
80 (43)
25(14)
144(77)
17(9)
124(66)
45 (24)
18(10)
98 (53)
86 (47)
153(83)
32(17)
40 (22)
112(62)
30(16)
56(31)
69 (38)
27(15)
30(16)
a
 Sociodemographic data were available in 185 and complete in 182
ases.
This category was not included in the regression analyses.
cases.
b
observations in the analysis instead of cutting the extremes. Timing of
QL assessment can affect patient's self-estimation [16]. Therefore, we
conducted additional analyses of the adjuvant then- minus pre-test,
post- minus pre-test and post- minus then-test in a subsample with
correct timing (n = 66) and investigated consistency. Patients fulfilling
the following criteria were included: In cases assigned to arms B or C,
the pre-test had to be filled in on day I of chemotherapy or within 21
days before; in all cases, the post-test had to be filled in within an
interval of 54 to 96 days after the pre-test, and the time difference
between then- and post-test had to be within 0 to 21 days.
Reframing effects (then- minus pre-test) and conventionally assessed
changes (post- minus pre-test) may be correlated either positively or
negatively depending on the magnitude and sign of post-test and then-
test. To investigate this association, we calculated the Pearson correla-
tion for each indicator.
A multiplicity problem arose due to tests performed on a series of
QL scores on the same patients. We did not adjust for multiple testing
because we did not rely on single p values but rather on patterns of
statistical significance over a range of scores. Lines indicating 95% CI
around observed mean effects help to assess visually such patterns
irrespective of the amount of statistical significance. All tests were
two-sided.
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Table 2. Surgery and adjuvant pre-test scores.a
Indicator
Physical well-being
Functional performance
Tiredness
Pain
Appetite
Nausea/vomiting
Mood
Anxiety
Perceived adjustment
Global quality of life
Surgery
n
130
130
130
129
130
129
130
128
130
129
Mean (SE)
74(2.1)
81 (2.0)
68(2.3)
78 (2.2)
77 (2.4)
89(1.6)
58 (2.4)
58 (2.7)
54 (2.6)
71(2.1)
Adjuvant phase
n
137
137
136
136
137
137
137
128
137
135
Mean (SE)
70(1.9)
66(2.3)
58 (2.2)
78 (2.0)
78 (2.0)
91(1.3)
69(1.9)
71 (2.2)
63 (2.4)
68(1.7)
a
 Secondary endpoints are in italics. All indicators range from 0-100.
Higher scores indicate better QL (e.g., less pain) in all indicators.
Results
Sample description
Overall, 215 patients were randomized in German
speaking centers. For this investigation, 187 patients
with at least one pair of corresponding questionnaires
for either pre/then-test comparison were selected (87%).
At the time of surgery, the main reason for missing QL
data were administrative problems at the local centers
(pre-test: 91%, then-test: 83% of all missing data). In the
adjuvant phase, QL data was mainly missing due to
patients' failure to send back the questionnaire (pre-test:
91%, then-test: 85%, post-test: 87% of all missing data).
Biomedical and sociodemographic characteristics are
described in Table 1. In brief, 59% of the patients were
male. The median age was 62 years, ranging from 27 to
88. Fourteen percent had a family history of colorectal
carcinomas. The majority underwent standard surgical
procedures. Fifty-three percent had no nodal involve-
ment. Eighty-three percent lived with next of kin or
friends. Seventy-eight percent had a formal professional
education. A minority had an upper level or academic
position. There was no major difference in these charac-
teristics between the responders and the non-responders
in the comparisons related to surgery and the adjuvant
phase.
Reframing under surgery
Thirteen patients (7%) had surgery-related complica-
tions, 21 (11%) had complications related to periopera-
tive chemotherapy, and 19 patients (10%) had other
complications. Surgery pre- and then-test assessments
were available in 132 patients (71%) of which 2 had
missing clinical information and were excluded. The
median time between the two assessments was 12 days
(range 6-73 days), close to the duration of hospital stay
(median 14 days, range 6-56 days). The surgery pre-test
scores are shown in Table 2.
After surgery, patients estimated their pre-surgery
Physical well-being
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Global quality of life
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Figure 3. Reframing under radical resection and perioperative chemo-
therapy (n = I30). Negative differences between then- and pre-test
(means with 95% CI) indicate worse scores of the retrospective estima-
tion (then-test).
physical measures (all P < 0.0004) and global QL
(P - 0.03) significantly lower than before, as shown in
Figure 3. The secondary endpoints showed consistent
findings, with worse retrospective estimations of func-
tional performance (P < 0.0001) and nausea/vomiting
(P - 0.001). The significant changes among all indicators
ranged from 4.6% (global QL) to 13% (tiredness) of full
scale range.
Refraining under adjuvant therapy or observation
Adjuvant pre- and then-test assessments were available
in 137 patients (74%). The median time between filling in
the questionnaire at the beginning of adjuvant therapy
or observation and the retrospective assessment was 50
days (range 13-80 days). Sixty-five percent of the patients
receiving chemotherapy filled in the pre-test question-
naire before or at day 1 of chemotherapy (range —40-
+45 days). The adjuvant pre-test scores are shown in
Table 2; they did not significantly differ among the three
treatment arms.
The changes between the assessment at the beginning
of the adjuvant phase (pre-test) and the retrospective
estimation (then-test) were not significantly affected by
treatment, with the exception of appetite (P - 0.03), as
shown in Figure 4. Patients under observation (arm A)
reported retrospectively better appetite than they did
before. Those receiving chemotherapy showed changes
in the opposite direction. The bigger change in patients
receiving 5-FU 450 mg/m2 plus Levamisol (arm B)
compared to those under observation was confirmed in
the multivariate analysis (effect size - 13.8, P - 0.003).
Investigating the three treatment arms together, pa-
tients estimated their physical well-being (P = 0.004),
mood {P = 0.0002) and global QL (P = 0.003) retro-
spectively lower than at the beginning of adjuvant ther-
apy or observation (Figure 4). The secondary endpoints
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Figure 4. Reframing under post-operative adjuvant chemotherapy or
observation (n = 137). Negative differences between then- and pre-test
(means with 95% CI) indicate worse scores of the retrospective estima-
tion (then-test) across treatments. Appetite is displayed by treatment
arm: A refers to Observation only, B to 5-FU 450 mg/m2 plus Levami-
sol and C to 5-FU 600 mg/m2.
anxiety (P = 0.04) and nausea/vomiting (P = 0.003)
similarly indicated worse retrospective estimations. The
significant changes were considerably smaller than those
under surgery and ranged from 4.5% (anxiety) to 7.5%
(mood) of full scale range. In the subsample with correct
timing (n = 66), the significant changes were consistently
larger than those of the total adjuvant sample and
ranged from 5% (global QL) to 9.3% (mood and anxiety)
of full scale range.
Factors affecting reframing
The multiple linear regressions of the differences be-
tween then- and pre-test yielded no consistent pattern
of biomedical or sociodemographic factors affecting
reframing. Their impact varied among the QL measures
and between the two situations. Under surgery, the
investigated factors accounted for only 10%-15% of the
variance of changes in four indicators (adj. R-squared),
in the adjuvant situation, for 10%-13% in three indica-
tors. This exploratory analysis did not change the inter-
pretation of the univariate findings.
Changes relative to beginning of treatment versus
retrospective estimation
Adjuvant pre- and then-test as well as post-test assess-
ment were available in 132 patients (71%). The median
time between the assessments of pre- and post-test was
64 days (range 21-143 days), and 14 days (range 0-93
days) between then-tests and the subsequent post-tests.
Based on conventionally assessed changes (post-
minus pre-test), functional performance (P = 0.04) and
nausea/vomiting (P = 0.0009) were the only measures
with a statistically significant treatment effect, as shown
(a)
Arm A
Arm B
ArmC
+
•
5 10 15
Changes in scores
(b)
Arm A
Arm B
ArmC
• •+
-20 -15 -10 -5 0
Changes in scores
15
Figure 5. Changes of (a) functional performance (n = 128) and (b)
nausea/vomiting (n = 129) by treatment relative to beginning of
adjuvant treatment versus retrospective estimation. A refers to obser-
vation only, B to 5-FU 450 mg/m2 plus Levamisol and C to 5-FU 600
mg/m2. The solid lines refer to conventionally assessed changes (post-
minus pre-test), the dashed lines to changes adjusted to patients'
retrospective estimation (post- minus then-test): positive differences
(means with 95% CI) indicate an improvement.
in Figure 5. Patients under observation (arm A) and
those receiving 5-FU 450 mg/m2 plus Levamisol (arm
B) reported an improvement in performance of about
15%, those with 5-FU 600 mg/m2 (arm C) indicated a
tendency only. Patients with B reported more worsening
in nausea/vomiting than those with C, whereas patients
under observation showed an improvement.
Patients' reframing was taken into account by com-
paring the assessment of current QL under treatment or
observation (post-test) to the retrospective estimation
(then-test) instead to the conventional assessment at the
beginning of treatment (pre-test). This adjustment diluted
the observed treatment effects (Figure 5). There was no
indication that this adjustment would reveal a treatment
effect in any of the remaining indicators. The subsample
with correct timing showed consistent findings.
This finding was explored regarding nausea/vomiting,
using physician ratings as an external criterion (arms B
and C): In cases physicians observed at least once dur-
ing the first three months nausea or vomiting of grade 2
or 3, patients indicated a greater worsening (post- minus
pre-test) in the corresponding indicator (n - 13, mean
change = -20.0, SE = 7.6) compared to those with grade
0 or 1 (« = 77, mean change = -8.5, SE = 2.6, P = 0.10).
The adjustment to patients' retrospective estimation
(post- minus then-test) diluted this effect: patients with
grade 2 or 3 indicated similar changes (n = 16, mean
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Figure 6. Changes across treatments relative to beginning of adjuvant
treatment versus retrospective estimation (n = 132). The solid lines
refer to conventionally assessed changes (post- minus pre-test), the
dashed lines to changes adjusted to patients' retrospective estimation
(post- minus then-test): positive differences (means with 95% CI)
indicate an improvement.
change = 3.0, SE = 7.9) compared to those with grade 0
or 1 0 = 73, mean change = -0.9, SE = 2.8, P = 0.58).
The remaining indicators not significantly affected by
treatment (post- minus pre-test) were investigated
across treatment arms. As shown in Figure 6, patients
indicated less tiredness (P - 0.02), better appetite
(P = 0.004) and less efforts to cope (P = 0.0005) under
adjuvant treatment or observation compared to the
beginning. The significant changes ranged from 4.9%
(appetite) to 7.3% (coping) of full scale range. After
adjustment to patients' retrospective estimation (post-
minus then-test), the overall improvement was substan-
tially amplified in most indicators, as shown in Figure 6.
The subsample with correct timing yielded consistent
findings with larger changes than in the total adjuvant
sample in both comparisons (post- minus pre-test, post-
minus then-test) and in all indicators.
The conventionally assessed changes and those at-
tributed to reframing (then- minus pre-test) were posi-
tively correlated in all indicators: The more the patients
reframed their past QL towards better (worse) scores the
greater the improvement (worsening) they reported over
time. The correlations ranged from ;• = 0.35 for appetite
(P = 0.0001) to r - 0.64 for functional performance
(P = 0.0001).
Discussion
The question whether cancer patients change the inter-
nal standards on which they base their QL estimation
has been debated for years. We addressed it within a
randomized clinical trial. Based on clinical observa-
tions, we investigated reframing as a broad concept of
changes in perception. We applied a specific theory
founded measure, the then-test [14], to clarify whether
this reframing actually amplifies treatment effects on
perceived QL.
Our first hypothesis, that patients change their inter-
nal standards on which they base their QL estimation,
is supported by our findings. Patients estimated their
pre-surgery QL and especially physical measures after
surgery lower than before, and their QL at the beginning
of adjuvant therapy or observation retrospectively also
lower than at that time. The findings regarding QL meas-
ures of complementary domains were mostly consistent.
The fact that there were similar effects in two different
clinical situations, regardless of hospital (surgery) or
home assessment (adjuvant situation) and despite varia-
tion in timing of QL assessment, supports their validity.
Our second hypothesis, that cytotoxic side-effects
would induce a greater shift in internal standards to
regain mental homeostasis, was not supported. Refram-
ing was not significantly affected by treatment, with the
exception of appetite. Although it seems plausible that
patients' reframing can be affected by a specific inter-
vention, in the adjuvant situation reframing appears to
be related more to patients' adaptation in a broader
sense (i.e., diagnosis and surgical sequelae). The fact
that reframing was not primarily induced by chemo-
therapy but was present to the same extent in the control
group points into this direction.
Overall, based on conventionally assessed changes
(post- minus pre-test), adjuvant chemotherapy had a
modest impact on QL, as reported by others [17]. It has
to be noted, however, that our sample is too small and
the follow-up too short to address this question exten-
sively. Across treatments, patients reported better scores
in physical measures and less effort to cope at two
months under adjuvant therapy or observation com-
pared to the beginning. Coping emotionally with having
colon cancer is a long-term process [5]. Patients indi-
cated no change in mood or anxiety but a change in
internal standard of these measures (then- minus pre-
test). There can only be speculation whether this refram-
ing precedes a forthcoming change also in emotional
measures.
The question is, whether reframing effects contribute
to our understanding of patients' QL in clinically rele-
vant transitions. The significance of psychological adap-
tation is grounded to some extent on patients' ability to
change their perception. Consequently, we compared
QL scores under adjuvant therapy or observation (post-
test) to patients' retrospective estimation (then-test) in-
stead of the conventional assessment at the beginning of
treatment (pre-test) [14]. This adjustment did dilute
treatment effects. This finding was conclusive when using
physician-rated nausea/vomiting as an external criterion.
We expected the opposite. However, the adjustment did
amplify the changes over time substantially. The pattern
suggests that patients' experience over the first months
may actually be different than documented by conven-
tional changes.
How are these conflicting findings to be interpreted?
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Howard et al. developed the then-test in healthy individ-
uals [14]. They observed that participants in communi-
cation skills workshops altered their perception as a
result of the intervention in a manner which contami-
nated self-assessment of the intervention (i.e., increased
awareness). Howard et al. accounted for this response-
shift by comparing scores after the intervention with
retrospective estimations of the baseline (then-test) in-
stead of the conventional baseline (pre-test) and were
able to demonstrate the effect of the intervention. In
cancer patients, this phenomenon is more complex. It is
plausible that a change in perception is not primarily
introduced by the intervention (e.g., treatment burden)
but by coping with the disease itself. For most patients,
living after being diagnosed with cancer is not the same
as before. In contrast to disease- and surgery-related
burden, cytotoxic side-effects are experienced mainly in
their acute phase and, overall, may be less of a burden
than the disease itself. These issues may explain why the
adjustment of QL scores to the retrospective estimation
amplified the changes overall but diluted the observed
treatment effects, stressing the dominant impact of
having cancer on QL. Similarly to this study, in patients
receiving adjuvant therapy for breast cancer, chemo-
therapy (CMF) had an adverse but minor impact on
QL compared to patients' adaptation following diagno-
sis and surgery [13].
It may be difficult for patients to estimate the past
experience [18]. Reframing may reflect memory effects.
Recall is not only dependent on time but also on the
individual significance of disease and treatment. If poor
memory were the only factor influencing the retrospec-
tive estimations, we would expect patients to report
better and worse retrospective scores in roughly equal
proportions. This was not the case, neither under surgery
nor in the adjuvant phase. In other words, the non-
random changes between pre- and then-tests cannot be
interpreted by memory effects only. We could not check
patients' understanding of the instructions or inquire
into their thoughts when filling in the questionnaire in
this multi-center trial. It has been shown that this type
of instruction can reliably be given by oral communica-
tion [4]. In our trial, patients were orally instructed for
the QL assessments related to surgery.
From a clinical point of view, our findings are in
agreement with numerous case reports on patients' abil-
ity to adjust to the many limitations of disease and
treatment. Providing patients with time perspective (e.g.,
duration of side-effects) may provoke reframing and
thereby support adaptation both in situations of im-
provement and deterioration. Another well-known phe-
nomenon of the way perception may change over time
has been reported in terminally-ill cancer and AIDS
patients. When things were going well, time was per-
ceived as passing more quickly than when things were
going badly [19]. Since reframing is obviously associated
with adaptation, health care professionals need to con-
sider this phenomenon.
Reframing effects are of relevance also for QL re-
searchers. Our data give grounds to base the evaluation
of QL on patients' subjective experience, complementary
to but distinguished from concepts such as health status
or functional disability. A patient's estimation of QL
may alter in response to changes in disease or treatment,
but it may also shift when there is little or no change in
specific clinical factors. For example, anticipation of
chemotherapy can have a substantial adverse impact on
QL, as shown for adjuvant therapy in patients with
breast cancer [13].
Considering adaptation, the relevance of population
norms for QL measures and the definition of clinically
meaningful changes both need attention. In essence,
norms are based on the assumption of stable internal
reference points and are often used in an absolute sense,
as for example the Karnofsky index. Given that patients'
subjective experience does change over time, and that
reframing is one facet of this process, QL endpoints
ideally reflect the weight of disease and treatment-related
issues salient for each individual patient and situation [20].
Is the standard approach of assessing changes relative
to baseline to be questioned? In our adjuvant setting, the
adjustment of scores to the retrospective estimation did
affect the interpretation of changes overall but reduced
the effect of treatments. Our data suggest that the then-
post-test does not invalidate the conventional pre-post-
test but addresses a different question; conventional
within-patient comparisons were mostly affected in
magnitude but not in direction by reframing. In another
study, patients with hairy cell leukemia indicated a dis-
parity between toxicities while on versus off long-term
therapy with interferon-a [21]. Their retrospective esti-
mates of fatigue and performance status under treatment
were also worse. In many studies based on conventional
comparisons cytotoxic treatment has shown a smaller
impact on QL than generally anticipated. The question
is raised whether patients' current or retrospective esti-
mation is more relevant for QL comparisons.
Further investigation is necessary to better understand
this phenomenon in both curative and palliative situa-
tions, in relation to supportive interventions, in other
chronic diseases and other QL measures. Regarding
clinical trials, the discriminating capacity of convention-
al comparisons versus comparisons taking into account
a measure of individual reframing needs to be clarified.
In conclusion, patients with colon cancer substan-
tially reframe their perception in estimating QL indica-
tors both under radical resection and under adjuvant
chemotherapy or observation. This effect is an integral
part of patients' adaptation to disease and treatment.
An understanding of this phenomenon is of particular
relevance for patient care. Its role in evaluating QL
endpoints in clinical trials needs further investigation.
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